HIV/ AIDS. Unspecified human immunodeficiency virus [HIV] disease
Conditions
Interventions
Intrvenous injection of IMOD one vial daily for three months. Each vial contains 4ml IMOD. It will be diluted in 100ml of dextrose 5% solution before injection and will be administered within one hour
Treatment - Drugs
Sponsors
Pars Roos Biotechnology Co.
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria • Diagnosis of HIV infection (two positive ELISA confirmed by one positive Western Blot test) • Receiving HAART • Age more than 18-75 Exclusion criteria • Evidence of malignancy (diagnosed or presenting a sign or symptom of major cancer such as hemoptysis, chronic cough, rectal bleeding, etc) except for Kaposi’s sarcoma • Presence of life threatening conditions such as hepatic or renal failure or congestive heart failure • Presence of life threatening infections or other serious and dangerous infections • Presence of liver function disorders in laboratory tests including elevation of liver enzymes or Bilirubin level more than 3 times of the upper limit of the normal range • Drug and alcohol abuse (more than 21 units alcohol for males and 14 units for females) • Treatment with corticosteroids, immune suppressants, radiotherapy or chemotherapy • Any known drug hypersensitivity • Inability or refusal to sign the informed consent • Receiving any investigational drug within 30 days prior to screening • Pregnancy or intention of becoming pregnant during the study period
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD4 Lymphocyte count. Timepoint: At the beginning, First, second, third and fourth month of study. Method of measurement: Flocytometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Viral load. Timepoint: At the beginning and end of the study. Method of measurement: Real Time Polymerase Chain Reaction test.;Quality of life. Timepoint: At the beginning and end of the study. Method of measurement: Questionaire. | — |
Countries
Syrian Arab Republic
Contacts
Public ContactDr. Faten Alakkad
Clinical trial Department
Outcome results
None listed